[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@JamesEKrause Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1091405261741404162.png) @JamesEKrause Biotech Jim

Biotech Jim posts on X about $crvs, $idya, $acrs, $nvo the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1091405261741404162/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:interactions.svg)

- X Week XXXXXX -XX%
- X Month XXXXXX +83%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +58%

### Mentions: X [#](/creator/twitter::1091405261741404162/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:posts_active.svg)

- X Week XX +50%
- X Month XX +12%
- X Months XXX -XX%
- X Year XXX +177%

### Followers: XXXXXX [#](/creator/twitter::1091405261741404162/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:followers.svg)

- X Week XXXXXX +0.29%
- X Month XXXXXX +1.90%
- X Months XXXXXX +8.60%
- X Year XXXXXX +18%

### CreatorRank: XXXXXXX [#](/creator/twitter::1091405261741404162/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1091405261741404162/influence)
---

**Social category influence**
[stocks](/list/stocks)  XX% [finance](/list/finance)  X% [technology brands](/list/technology-brands)  X%

**Social topic influence**
[$crvs](/topic/$crvs) #1, [$idya](/topic/$idya) 8%, [$acrs](/topic/$acrs) #1, [$nvo](/topic/$nvo) #150, [$imrx](/topic/$imrx) 4%, [$23b](/topic/$23b) 4%, [$acls](/topic/$acls) 4%, [friends with](/topic/friends-with) 4%, [$mdgl](/topic/$mdgl) 4%, [$mash](/topic/$mash) X%

**Top accounts mentioned or mentioned by**
[@playertwoq](/creator/undefined) [@seedy19tron](/creator/undefined) [@snupsnus](/creator/undefined) [@dudebiotech](/creator/undefined) [@cashinsider](/creator/undefined) [@wallstsai](/creator/undefined) [@badinvestor99](/creator/undefined)

**Top assets mentioned**
[IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Novo-Nordisk (NVO)](/topic/$nvo) [Axcelis Technologies Inc (ACLS)](/topic/$acls) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Pfizer, Inc. (PFE)](/topic/$pfe)
### Top Social Posts [#](/creator/twitter::1091405261741404162/posts)
---
Top posts by engagements in the last XX hours

"$IMRX Company PR on pancreatic patient data update with Tebimetinib + MGNP note on stock offering and a Reuters News Brief. Sept XX (Reuters) 5:21 PM ET Immuneering Corp * IMMUNEERING ANNOUNCES EXTRAORDINARY XX% OVERALL SURVIVAL AT X MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP * IMMUNEERING CORP(IMRX) - ATEBIMETINIB + MGNP SHOWS XX% PFS AT X MONTHS IN PANCREATIC CANCER * IMMUNEERING CORP(IMRX) - EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 * IMMUNEERING CORP(IMRX) - TO INITIATE PIVOTAL TRIAL BY END OF 2025"  
[X Link](https://x.com/JamesEKrause/status/1971000627325988965) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-24T23:55Z 13.2K followers, 6955 engagements


"Performing some DD on $IDYA IDEAYA Biosciences trying to get a synopsis of their many biopharma collaborations. New to this name fwiw. Some friends of mine on X believe this company may be a buyout candidate. Current mkt cap $2.3B with some uncertainty of # of fully diluted shares (stock option grants etc). As usual please feel free to provide commentary (+ and -) on this interesting company/business plan. Partnered Programs and Collaborative Details via Grok my consultant. IDEAYA Biosciences has established multiple strategic partnerships to advance its precision oncology pipeline focusing"  
[X Link](https://x.com/JamesEKrause/status/1977085929811583266) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-11T18:56Z 13.2K followers, 16.7K engagements


"$CRVS is starting to get recognized"  
[X Link](https://x.com/JamesEKrause/status/1978536636733391182) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-15T19:01Z 13.2K followers, 10.1K engagements


"Regarding the accurate spelling of Aclaris $ACLS. Disclosure: I picked up some share ystdy for the 2026 ews flow. Never really followed the company before as they are friends with the 'bad luck bears'. Their approaches today are reasonable but 2026 is do or die. Activist investors such as Kevin T may have helped buoy the ship but it is all about the next yr company trial readouts. For the #ITK inhibitor with more acute selectivity (IND in 2026) this may be too little too late if the clintrials do not pan out. I invested since I like the risk reward but I sure would like to know the FDA regs"  
[X Link](https://x.com/JamesEKrause/status/1978577493327331655) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-15T21:43Z 13.2K followers, 1382 engagements


"Madrigal's CEO Bill Seybold discusses the $MDGL $MASH market and sales on CNBC"  
[X Link](https://x.com/JamesEKrause/status/1978953279380787610) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-16T22:36Z 13.2K followers, 3891 engagements


"Grok for the purposes of continuing due diligence tell me about the business plan pipeline most valuable asset the management and investors in Ideaya Biosciences $IDYA"  
[X Link](https://x.com/JamesEKrause/status/1979549315434770694) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-18T14:05Z 13.2K followers, 1893 engagements


"On the ITK enzyme and its inhibition for TH2 inflammatory diseases. I will be listening in on the Aclarus presentations today: Aclaris Therapeutics to Host In-Person and Webcast R&D Day Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets in New York on October XX 2025 $ACRS $CRVS"  
[X Link](https://x.com/JamesEKrause/status/1978082130614698409) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-14T12:55Z 13.2K followers, 8782 engagements


"$NVO Novo Nordisk to Acquire Akero Therapeutics for Up to $XXX Billion"  
[X Link](https://x.com/JamesEKrause/status/1976252303830380791) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-09T11:44Z 13.2K followers, 2021 engagements


"On fictitious scientific authors in this day/age of #AI 👇"  
[X Link](https://x.com/JamesEKrause/status/1980950591317676351) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-22T10:53Z 13.2K followers, 2294 engagements


"Key insight on $VKTX in my view as well: "Only one explanation for all that pill fatigue ( X large tabs ) and not due to drug toxicity per se. Per CEO easily fixable issue which I believe so as $NVO packages XX mg of similar oral sema plus XXX mg SNAC in one average size tab." Pill burden followed by pill fatigue can be and herein seems to be the real deal. CMC scientists/peptide chemists of huge help here an art in its own. Especially for peptides somewhat modified for t1/2 et al. BTW my fav (neuro)peptide by a long shot is RPKPQQFFGLMamide"  
[X Link](https://x.com/JamesEKrause/status/1980998502282104863) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-22T14:03Z 13.2K followers, XXX engagements


"$CRVS $ACRS $PFE Here are some of the top/leading/reference T cell #ITK inhibitors not including antibody mechanisms. From both ChatGPT and from Grok. Aclaris Therapeutics holds patents on chemical compositions that inhibit the ITK enzyme primarily ATI-2138 a covalent dual inhibitor of ITK and JAK3 kinases. The exact proprietary chemical composition of ATI-2138 is not publicly disclosed in press releases but is detailed in patent filings. One such patent is WO-2020033955-A1 which broadly covers arylpyridinone compounds used for ITK inhibition. Of course Corvus has their own set of ITK"  
[X Link](https://x.com/JamesEKrause/status/1981078217197777376) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-22T19:20Z 13.2K followers, 2306 engagements